Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 14Carcinoma, Hepatocellular 8Nasopharyngeal Carcinoma 7Esophageal Neoplasms 6Neoplasm Metastasis 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Melanoma 4Advanced NSCLC 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Rectal Neoplasms 3Pancreatic Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Neoplasms 2Lung Neoplasms 2Locally Advanced Rectal Cancer 2Leukemia, Myeloid, Acute 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1

Interventions

pembrolizumab 1Nivolumab 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Efficacy, Team × Immune Checkpoint Inhibitors × Clear all
NCT06693440 2024-11-18

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Henan Cancer Hospital

Recruiting
3,000 enrolled

Efficacy, Team

Data powered by HemOnc (CC BY 4.0) Colophon âš¡